… This study examined the effects of dapagliflozin according to the presence … heart disease,
and elevated N-terminal pro–B-type natriuretic peptide levels were randomized to dapagliflozin …

… LVEF similarly across all regions studied (Figure 1). The benefit of dapagliflozin on the
primary outcome was not modified by region: hazard ratio for dapagliflozin versus placebo 0.85 (…

… Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive
either dapagliflozin (at … The primary outcome was a composite of worsening heart failure (…

… study, which was designed to study the effect of dapagliflozin … Hence, further studies
investigating the effects of dapagliflozin in … in our study was as low as 27.2 in the dapagliflozin …

… DELIVER is a global randomized, double-blind, parallel-… of dapagliflozin with placebo in
patients with heart failure (HF) … financial support for the DELIVER study from AstraZeneca; …

… outcome of cardiovascular death or worsening heart failure (HF) in … In this study, we explored
whether the effect of dapagliflozin … We also examined the effect of dapagliflozin on kidney …

… Dapagliflozin in patients with heart failure and reduced ejection fraction.  … In this study,
sex modified the effect of dapagliflozin on the mean change in KCCQ-TSS from baseline to 8 …

… In our study, the mean age was 81 years, and 59% of patients were women. In the DELIVER
trial, the benefits of dapagliflozin were independent of age or sex, emphasizing its use in all …

… , in a real-word heart failure population. Our results from the Swedish Heart Failure
Registry show that a great number of patients with heart failure might be candidates for these …

… OBJECTIVES This study … Heart Failure) trial, using previously validated actuarial methods,
we extrapolated the potential gains in event-free survival from long-term use of dapagliflozin in …